Nxera Pharma

Update in progress

4565.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Nxera Pharma Co., Ltd. is a biopharmaceutical company developing drugs in Japan, the US and abroad. It operates a GPCR-focused platform called NxWave and a diverse pipeline: PIVLAZ and QUVIVIQ; NBI-1117568 (M4 agonist, Phase 3); ORX750 (OX2 agonist); NBI-1117570 (M1/M4 dual agonist); HTL0039732 (EP4 antagonist). Phase 1 programs include PF-07054894, NXE0033744, PF-07258669, NBI-1117569, NBI-1117567, TMP-301 and NXE0048149. Preclinical assets include KY1051 and NXE0027477. Collaborations span Tempero Bio, Sanofi, Lilly, AbbVie, Pfizer, Genentech, Novartis and more. Formerly Sosei Group; founded 1990; headquartered in Minato, Japan.

Company score

Sentiment: 0.13; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.09; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive